Schrödinger today announced that new preclinical data on SGR-3515 and SGR-4174 will be presented at the AACR Annual Meeting ...

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

“We continue to enroll patients in the ACESOT-1051 trial evaluating our WEE1 kinase inhibitor, APR-1051, which we believe has best in class potential. The compound appears safe and well ...

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ...

Presentations include preclinical data on Wee1/Myt1 inhibitor SGR-3515 and SOS1 inhibitor SGR-4174 Schrödinger, Inc. (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515 ...

Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...

H.C. Wainwright lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $19 from $22 and keeps a Buy rating on the shares. The firm ...

Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Improved safety window compared to single-target WEE1 inhibitors The Phase I clinical trial, set to launch in 2025, will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor ...